What's powering the tide of innovation in patient connectivity? Are you positioned to catch the wave? A generational shift toward mobile connectivity, technology advancements that allow for big data processing and analytics, and changes to healthcare models are all part of this massive shift; how does your company fit in?
Join Johnson & Johnson Innovation for a discussion about positioning your company for innovation success. Topics include the digital trends of the connected patient, business model considerations and scaling, as well as integrating multiple inputs in order to keep the patient at the center of your solution.
Samir Damani | Founder & Chief Executive Officer, MD Revolution read bio»
Alexander Grunewald | Global Head - Healthcare Innovation Strategy, Johnson & Johnson Innovation read bio»
Mark Oswald | VP of Technology, MedImpact Direct read bio»
Julie Papanek | Healthcare Venture Capitalist, Canaan Partners read bio»
Steven Steinhubl | Director of Digital Medicine, Scripps Translational Science Institute; Clinical Cardiologist, Scripps Health read bio»
3:30 PM | Registration Opens, Networking
4:00 PM | Panel Discussion
5:15 PM | Networking Reception
6:00 PM | Program Close
Who should attend:
Digital health companies and startups, entrepreneurs, advisors & investors.
$35 | General Public
$20 | Student/Academic
$45 | At the door
This event is presented in partnership with CONNECT
3210 Merryfield Row
San Diego, CA
Samir Damani, MD, PharmD, FACC | Founder & Chief Executive Officer, MD Revolution
Dr. Damani is MD Revolution's Founder and CEO, as well as a recognized change agent in healthcare. Leading a group of experienced healthcare and technology leaders, MD Revolution is actively addressing change in healthcare by empowering patients and providers to focus on "health" care and away from episodic illness care. Dr. Damani and team are delivering excellence in chronic care management through innovative approaches to patient engagement and remote care delivery. MD Revolution's chronic care management solution has been implemented across small and large provider group settings for thousands of patients and has enabled value based care and new revenue streams for physicians across the nation. Dr. Damani and his MD Revolution clinical & analytics teams have demonstrated outstanding clinical outcomes in patients by digitizing a data driven and highly personalized healthcare experience. He conceived and enabled the development of RevUp, MD Revolution's scalable, secure, and proprietary patient engagement technology platform. RevUp is the only chronic care management tool with proven capabilities for new clinical knowledge creation via machine learning, while also providing highly secure messaging capabilities via a remote clinical care team. In addition to leading the company's day to day operations and having raised over $30 million in financing for MD Revolution's health care changing efforts, Dr. Damani has directed numerous studies, including one on biomarkers of heart attacks sponsored by the National Institutes of Health. He has also written over 40 articles and book chapters, and has spoken at national and international forums on personalized medicine, genomics, digital health, and wellness. He has served as a scientific advisor for the prominent journal, Science Translational Medicine, and continues to serve as a reviewer for Nature Genetics, Annals of Internal Medicine, American Journal of Cardiology, and the Journal of the American College of Cardiology. Samir also serves as a Clinical Instructor in the Department of Family & Preventive Medicine for the UC San Diego Medical School and is a board-certified practicing cardiologist at the top 20 US News and World Report heart care center, Scripps Clinic in San Diego.
Connect with Samir:
Alexander Grunewald, Ph.D. | Global Head - Healthcare Innovation Strategy, Johnson & Johnson Innovation
Alexander leads external innovation in Health Solutions and Digital Health at Johnson & Johnson. His team's focus areas include improving patient outcomes, enhancing wellness of healthy consumers, driving R&D operational advances, and exploring digital therapeutics and genomics. Alexander began his career in academia, first as a senior postdoctoral scholar in neuroscience at the California Institute of Technology and then as an assistant professor at the University of Wisconsin-Madison. During that time he was published in numerous important research articles, led a visual neurophysiology research team, and taught neuroscience to undergraduate and graduate students. He then transitioned into industry where he led client engagements in strategy, sales and operations for healthcare companies as a health care leader at McKinsey & Company in Los Angeles. From there he transitioned to running the Drug Compare business at DestinationRx, Inc., a healthcare IT company. He also served as senior director of corporate strategy and business development at McKesson. In this role, he led his team to define the strategy and M&A for the company's U.S. Pharma and Specialty businesses. Alexander has a Ph.D. in Computational Neuroscience from Boston University and a B.Sc. in Mathematics from King's College in London, England.
Connect with Alexander:
Mark Oswald | Vice President of Technology, MedImpact Direct
Mark Oswald is Vice President of Technology at MedImpact Direct where he leads the technology strategy and product team for MedImpact's patient-facing solutions. He is passionate and focused on technology innovation and the opportunity to have a meaningful impact on people's lives. Mark has over 25 years of leadership experience in healthcare, including roles at large organizations such as IBM, Microsoft, and Janssen, as well as the start-up world. He was developing EMRs in the 80's, before they were even called EMRs. Mark is problem-oriented and is now trying to understand and solve problems related to patient "connectivity" and engagement.
Connect with Mark:
Julie Papanek | Healthcare Venture Capitalist, Canaan Partners
Julie Papanek is a healthcare venture capitalist at Canaan Partners, a multi-sector early stage VC firm with over $3 billion under management. She primarily leads investments in pharmaceutical and digital health start-ups. Currently Julie sits on the board of Protagonist Therapeutics and observes on the board of Chrono Therapeutics and Glooko. Previously, Julie observed on the boards of Labrys Biologics, Dermira (DERM), ALDEA Pharmaceuticals, and CytomX Therapeutics (CYTM). Before arriving at Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development and business development. Julie is passionate about mentoring entrepreneurs, improving clinical outcomes and expanding consumer access to healthcare. Beyond her work with portfolio companies, Julie is an advisor to the BIO Annual International Conference and is a National Cancer Institute grant reviewer. She holds an MBA from Stanford, a Master's Degree from the Biotechnology Institute at Cambridge University and a BSc in Molecular Biophysics & Biochemistry from Yale University.
Connect with Julie:
Steven R. Steinhubl, MD | Director of Digital Medicine, Scripps Translational Science Institute; Clinical Cardiologist, Scripps Health
Dr. Steinhubl is the Director of Digital Medicine at the Scripps Translational Science Institute and a clinical cardiologist at Scripps Health. He received his undergraduate training in engineering at Purdue University, graduate training in physiology at Georgetown University, and his medical degree at St. Louis University. Steve's residency training was completed at David Grant USAF Medical Center and his cardiology fellowship at the Cleveland Clinic. Prior to joining Scripps Steve was the Director of Cardiovascular Wellness and the Medical Director for Employee Wellness for the Geisinger Healthcare System. As a clinician-scientist Dr Steinhubl's research activities have focused on clinical trials of novel therapeutic interventions to improve outcomes, ranging from the study of novel antithrombotic therapies to the application of an integrated systems-based approach for the optimal identification, communication and treatment of individual risk. He has been principal investigator or helped lead over a dozen large-scale, international randomized trials and has authored nearly 200 peer-reviewed manuscripts as well as numerous book chapters, and abstracts. At Scripps, through the development and oversight of a portfolio of clinical trials, Steve is responsible for helping develop the evidence base necessary to establish the role of mobile health technologies in the transformation of healthcare.
Connect with Steven:
When & Where
JLABS San Diego
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.